Gunderson Dettmer, Goodwin Procter and Google Cloud collaborate to accelerate frontier tech commercialization

NEW YORK and BERKELEY, Calif., June 4, 2026 /PRNewswire/ — Hivemind Capital, a leading investment firm specializing in deep technology, today announced the launch of darkmatter lab, a first-of-its-kind program and cornerstone initiative of the firm’s upcoming venture fund, designed to accelerate the commercialization of frontier technologies by supporting researchers at the earliest stages of development – before company formation. Launched in partnership with University of California, Berkeley, and with Gunderson Dettmer, Goodwin Procter and Google Cloud, darkmatter lab introduces a new model for bringing advanced research out of academic labs and into real-world applications.

The partnership was created to address the structural gaps in frontier tech funding, including declining federal research support, corporate funding that typically requires IP concessions and traditional venture capital’s inability to engage until research has already exited the university system.

“Too many of the most important breakthroughs never make it out of the lab, or take years to do so,” said Emmanuel Vallod, Head of Venture and Research at Hivemind Capital. “The most consequential work happens before a company exists, but that’s also when resources are most limited. darkmatter lab is built to support researchers at that moment, with the capital, compute and expertise needed to move from idea to deployment.”

Each selected project will receive at least $1 million in resources, including research funding from Hivemind Capital, $350,000 in compute credits from Google Cloud through its Google for Startups Cloud Program, immigration, IP and incorporation legal support from Gunderson Dettmer and Goodwin Procter, and comprehensive operating services through Berkeley SkyDeck, UC Berkeley’s platform for innovation and entrepreneurship resources.

darkmatter lab will initially support projects across high-impact areas of AI and blockchain, including AI infrastructure, agentic systems, cybersecurity, compute optimization, cryptography and decentralized systems.

“UC Berkeley has always been where foundational research becomes transformative technology,” said Rich Lyons, Chancellor of UC Berkeley. “Our researchers are working on some of the most important problems in AI and blockchain, and they deserve resources that match the ambition of their work. Hivemind understands the role research plays in driving innovation forward, and darkmatter lab is exactly the kind of partnership universities need right now: patient, research-first capital that keeps our researchers in control of their work.”

About Hivemind Capital
Hivemind Capital is a global investment group operating at the intersection of traditional finance and the onchain economy. Founded in 2021, Hivemind allocates institutional capital across a diverse set of investment strategies, and implements technology infrastructure to help assets and institutions transition onto blockchain rails with discipline, durability, and scale. Learn more at hivemind.capital.

About UC Berkeley
Founded in 1868, UC Berkeley is the world’s No. 1 public university, with 63 Nobel laureates and 50 graduate programs ranked in the nation’s top 10. Berkeley researchers advance fundamental science while addressing society’s greatest challenges — from artificial intelligence to climate change to human health. The university enrolls nearly 46,000 students, with 28% of undergraduates receiving federal Pell Grants, reflecting its commitment to access. Learn more at berkeley.edu.

View original content:https://www.prnewswire.com/news-releases/hivemind-capital-and-uc-berkeley-launch-darkmatter-lab-a-first-of-its-kind-program-and-cornerstone-of-hiveminds-upcoming-venture-fund-302791095.html

SOURCE Hivemind

ST. PETERSBURG, Fla., June 4, 2026 /PRNewswire/ — ARTAN Bio, a longevity biotechnology company based in St. Petersburg, Florida, today announced the completion of a $200,000 seed raise. The raise will fund preclinical advancement of ARTAN Bio’s proprietary engineered suppressor platform, which targets nonsense mutations — a class of genetic errors responsible for premature protein translation stops that underlie a wide range of aging-related and genetic diseases.

About the Technology

ARTAN Bio has developed a novel engineered suppressor tRNA system (ARTAN-102) designed to selectively recognize disease-causing nonsense codons and restore normal protein translation. Unlike broad-spectrum approaches, ARTAN Bio’s mutation-specific platform offers a targeted strategy with potential application across multiple aging-associated conditions. The company has successfully completed initial in-cell validation of ARTAN-102 via an earlier seed raise with VitaDAO.

Proceeds from the raise will fund the next stage of development, including validation of the suppressor system in animal models, advancement toward a preclinical development candidate, and intellectual property filings to protect the platform’s innovations.

Leadership Comments

“This raise marks an important inflection point for ARTAN Bio,” said Anthony Schwartz, Ph.D., Chief Executive Officer of ARTAN Bio. “We are building a platform with real potential to address the genetic underpinnings of aging, and we’re doing it through an open, community-driven model that hasn’t been possible before. I look forward to sharing our progress with the global longevity and DeSci community at the NFC Summit (Non-Fungible Conference) in Lisbon on June 4th.”

“Nonsense mutations represent a largely untapped vulnerability in aging and age-related disease,” said Michael Torres, Ph.D., Chief Scientific Officer of ARTAN Bio. “Having validated our engineered suppressor system in cell models, we are now positioned to demonstrate its efficacy in vivo. This raise through VitaDAO’s decentralized science model gives us the capital and the community to take that next step.”

Anthony Schwartz, Ph.D. will present ARTAN Bio at the NFC Summit in Lisbon, Portugal on June 4th, 2026, where he will discuss the company’s platform, its VitaDAO partnership, and the decentralized science model driving its development.

About the VITARNA Token

$VITARNA tokens represent fractions of governance rights over the Mutation-Specific Codon Suppression for Aging and Longevity IP-NFT. The primary issuance is offered via the Molecule AG platform. Token holders participate in governance decisions including research prioritization, IP licensing strategy, and allocation of research funds — a model that democratizes early-stage biotech funding and aligns scientific progress with community stakeholders.

About ARTAN Bio

ARTAN Bio is a longevity biotechnology company headquartered in St. Petersburg, Florida at spARK Labs by ARK Invest. The company is developing mutation-specific codon suppression technologies to address genetic diseases and aging-related conditions caused by nonsense mutations. ARTAN Bio’s platform delivers engineered suppressor systems through clinically validated modalities to restore protein function in affected cells.

About VitaDAO

VitaDAO is a decentralized autonomous organization dedicated to funding and advancing longevity science research. VitaDAO supports early-stage research projects through its IP-NFT model, enabling broad community participation in the governance of longevity IP. More information is available at vitadao.com.

This press release is for informational purposes only. VITARNA tokens are not securities and this release does not constitute an offer or solicitation to purchase financial instruments.

View original content to download multimedia:https://www.prnewswire.com/news-releases/artan-bio-raises-200-000-in-decentralized-funding-to-advance-longevity-science-through-mutation-specific-codon-suppression-302789887.html

SOURCE ARTAN BIO

Largest professional services network recognizes Configit’s excellent management across four key functions

COPENHAGEN, Denmark, June 4, 2026 /PRNewswire/ — Configit, the global leader in Configuration Lifecycle Management (CLM), today announced its inclusion in Deloitte’s Best Managed Companies award list for Denmark in 2026.

The Best Managed Companies award recognizes excellence among Danish businesses. The program annually evaluates whether companies excel in their growth strategies across all key management functions: Strategy, Culture and Commitment, Capabilities and Innovation, and Governance and Financials.

Participating companies are benchmarked during this process against a common evaluation framework, using a comprehensive application and coaching process. The program ends with an exclusive award ceremony, celebrating only the best in class.

Configit is a trusted leader in Configuration Lifecycle Management (CLM), providing market-leading global manufacturers with business-critical solutions for the configuration of complex products. Based on the patented Virtual Tabulation (VT)™ technology, Configit’s solutions enable companies to reduce time to market, increase quality of configurable products and improve process efficiency.

Johan Salenstedt, CEO, Configit, said: “As AI quickly transforms manufacturing, we are enabling discrete manufacturing companies to get configurable products and services to market faster and more effectively. We help unlock the value of AI as companies embark on those mission-critical digital transformation projects. It’s gratifying to see our hard work recognized, especially by an organization like Deloitte.

Achievements like this do not happen because of a management team, a strategy document, or a set of processes alone. They happen because every employee contributes every day to turning our strategy into action, living our values, embracing our culture, and consistently applying the frameworks and guidelines that help us operate as one global company.”

About Configit
Configit is the global leader in Configuration Lifecycle Management (CLM) solutions and a supplier of business-critical software for the configuration of complex products. All Configit products are based on the patented Virtual Tabulation® (VT™) technology, which has redefined product configuration by offering greater speed and better handling of complexity. Virtual Tabulation enables Configit to deliver powerful, easy-to-use configuration solutions to market-leading global enterprises. Website: configit.com

Media Contact:
Diana Diaz 
Force4 Technology Communications
diana.diaz@force4.co

View original content to download multimedia:https://www.prnewswire.com/news-releases/configit-named-by-deloitte-as-one-of-denmarks-best-managed-companies-302791001.html

SOURCE Configit